sellModerate cluster of 2
Avalon Ventures XI, L.P. sold $77M of JANX
owner at Janux Therapeutics, Inc.. 1,673,128 shares at an average of $46.30, traded Oct 16, 2024, filed Oct 18, 2024.
Warning score
50Value
$77M
1,673,128 shares
Holdings after
2,115,373
-59% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +12Role10% owner
- +25Trade size$77.5M at market
- +20Share of holdings soldSold 59% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -2.5%, 3m -18.6%, 6m -40.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
JANXOct 9, 2026 · close 18.39
Since filing Oct 18, 2024: -63.2%SPY +36.3% · excess -99.5%
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-025436, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 16, 2024 | SOpen-market sale Common Stock | -60,179 | $49.69 | $3.0M | 2,761,291 | Oct 18, 2024 |
| Oct 16, 2024 | SOpen-market sale Common Stockindirect: By Avalon BioVentures I, LP | -11,657 | $49.69 | $579k | 534,883 | Oct 18, 2024 |
| Oct 16, 2024 | SOpen-market sale Common Stockindirect: By Avalon BioVentures SPV I, L.P. | -61,445 | $49.69 | $3.1M | 2,819,366 | Oct 18, 2024 |
| Oct 16, 2024 | SOpen-market sale Common Stock | -29,474 | $50.61 | $1.5M | 2,731,817 | Oct 18, 2024 |
| Oct 16, 2024 | SOpen-market sale Common Stockindirect: By Avalon BioVentures I, LP | -5,710 | $50.61 | $289k | 529,173 | Oct 18, 2024 |
| Oct 16, 2024 | SOpen-market sale Common Stockindirect: By Avalon BioVentures SPV I, LP | -30,094 | $50.61 | $1.5M | 2,789,272 | Oct 18, 2024 |
| Oct 16, 2024 | MOption exercise Common Stock | +4,968 | $17.00 | $84k | 11,855 | Oct 18, 2024 |
| Oct 16, 2024 | MOption exercise Common Stock | +2,070 | $10.73 | $22k | 13,925 | Oct 18, 2024 |
| Oct 16, 2024 | MOption exercise Common Stock | +2,070 | $13.22 | $27k | 15,995 | Oct 18, 2024 |
| Oct 16, 2024 | MOption exercise Common Stock | +1,407 | $39.80 | $56k | 17,402 | Oct 18, 2024 |
| Oct 16, 2024 | SOpen-market sale Common Stock | -10,957 | $50.80 | $557k | 6,445 | Oct 18, 2024 |
| Oct 17, 2024 | MOption exercise Common Stock | +836 | $17.00 | $14k | 7,281 | Oct 18, 2024 |
| Oct 17, 2024 | MOption exercise Common Stock | +348 | $10.73 | $3,734 | 7,629 | Oct 18, 2024 |
| Oct 17, 2024 | MOption exercise Common Stock | +348 | $13.22 | $4,601 | 7,977 | Oct 18, 2024 |
| Oct 17, 2024 | MOption exercise Common Stock | +237 | $39.80 | $9,433 | 8,214 | Oct 18, 2024 |
| Oct 17, 2024 | SOpen-market sale Common Stock | -1,843 | $50.02 | $92k | 6,371 | Oct 18, 2024 |
| Oct 18, 2024 | SOpen-market sale Common Stock | -102,732 | $50.30 | $5.2M | 2,629,085 | Oct 18, 2024 |
| Oct 18, 2024 | SOpen-market sale Common Stockindirect: By Avalon BioVentures I, LP | -19,900 | $50.30 | $1.0M | 509,273 | Oct 18, 2024 |
| Oct 18, 2024 | SOpen-market sale Common Stockindirect: By Avalon BioVentures SPV I, L.P. | -104,892 | $50.30 | $5.3M | 2,684,380 | Oct 18, 2024 |
| Oct 18, 2024 | SOpen-market sale Common Stock | -15,462 | $51.18 | $791k | 2,613,623 | Oct 18, 2024 |
| Oct 18, 2024 | SOpen-market sale Common Stockindirect: By Avalon BioVentures I, LP | -2,995 | $51.18 | $153k | 506,278 | Oct 18, 2024 |
| Oct 18, 2024 | SOpen-market sale Common Stockindirect: By Avalon BioVentures SPV I, L.P. | -15,788 | $51.18 | $808k | 2,668,592 | Oct 18, 2024 |
| Oct 18, 2024 | SOpen-market sale Common Stock | -541,824 | $44.75 | $24M | 2,071,799 | Oct 18, 2024 |
| Oct 18, 2024 | SOpen-market sale Common Stockindirect: By Avalon BioVentures I, LP | -104,957 | $44.75 | $4.7M | 401,321 | Oct 18, 2024 |
| Oct 18, 2024 | SOpen-market sale Common Stockindirect: By Avalon BioVentures SPV I, L.P. | -553,219 | $44.75 | $25M | 2,115,373 | Oct 18, 2024 |
| Oct 16, 2024 | MOption exercise Stock Option (right to buy)derivative | -4,968 | $0.00 | $0 | 22,776 | Oct 18, 2024 |
| Oct 16, 2024 | MOption exercise Stock Option (right to buy)derivative | -2,070 | $0.00 | $0 | 9,490 | Oct 18, 2024 |
| Oct 16, 2024 | MOption exercise Stock Option (right to buy)derivative | -2,070 | $0.00 | $0 | 9,490 | Oct 18, 2024 |
| Oct 16, 2024 | MOption exercise Stock Option (right to buy)derivative | -1,407 | $0.00 | $0 | 6,309 | Oct 18, 2024 |
| Oct 17, 2024 | MOption exercise Stock Option (right to buy)derivative | -836 | $0.00 | $0 | 21,940 | Oct 18, 2024 |
| Oct 17, 2024 | MOption exercise Stock Option (right to buy)derivative | -348 | $0.00 | $0 | 9,142 | Oct 18, 2024 |
| Oct 17, 2024 | MOption exercise Stock Option (right to buy)derivative | -348 | $0.00 | $0 | 9,142 | Oct 18, 2024 |
| Oct 17, 2024 | MOption exercise Stock Option (right to buy)derivative | -237 | $0.00 | $0 | 6,072 | Oct 18, 2024 |
Related signals
Other insiders at Janux Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Janux Therapeutics, Inc. | Andrew Hollman Meyer Chief Business Officer | $110k 3,333 shares | -4% | |
| 0Weak | Janux Therapeutics, Inc. | Andrew Hollman Meyer Chief Business Officer | $100k 3,333 shares | -4% | |
| 3Weak | Janux Therapeutics, Inc. | Andrew Hollman Meyer Chief Business Officer | $501k 16,665 shares | -17% | |
| 0Weak | Janux Therapeutics, Inc. | Andrew Hollman Meyer Chief Business Officer | $107k 3,333 shares | -4% | |
| 0Weak | Janux Therapeutics, Inc. | Andrew Hollman Meyer Chief Business Officer | $100k 3,334 shares | -4% | |
| 43Moderate | JANXbuy Janux Therapeutics, Inc. | Ra Capital Management, L.p. director, owner | $25M 824,041 shares | +9% | |
| 0Weak | Janux Therapeutics, Inc. | Andrew Hollman Meyer Chief Business Officer | $107k 3,334 shares | -4% | |
| 0Weak | Janux Therapeutics, Inc. | Andrew Hollman Meyer Chief Business Officer | $141k 3,334 shares | -4% | |
| 27Weak | Janux Therapeutics, Inc. | David Alan Campbell President and CEO | $300k 5,000 shares | -2% | |
| 29Weak | Janux Therapeutics, Inc. | Andrew Hollman Meyer Chief Business Officer | $732k 13,334 shares | -14% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.